Pharminent

J&J, Roche among companies selected for FDA digital health pilot

The regulator hopes to improve how it reviews digital medical devices, aiming to streamline the path to market for new health tools. http://www.healthcaredive.com/news/apple-fitbit-among-companies-selected-for-fda-digital-health-precertificat/505867/

Filed under: Company

Novartis’ CAR-T drug needs new payment model, says Express Scripts

Cost of Novartis’ revolutionary therapy is obstacle, says CMO.
The post Novartis’ CAR-T drug needs new payment model, says Express Scripts appeared first on Pharmaphorum. https://pharmaphorum.com/news/novartis-car-t-expensive-us-health-system-express-scripts/

Filed under: Payer

How Startups Are Trying To Overcome India’s Healthcare Challenges

As Health Care Industry is projected to grow by 17% (compounded annual growth rate) by 2020; startups are attempting to overcome problems such as poor health infrastructure, low levels of insurance, and rural vs urban disparity that are plaguing health services in India. https://www.forbes.com/sites/krnkashyap/2017/09/25/how-startups-are-trying-to-overcome-indias-healthcare-challenges/

Filed under: Emerging Markets

New Infographic: A Response to “A Better Deal” on Drug Pricing

The United States is the global leader in biomedical innovation, discovering more new cures than … http://www.biotech-now.org/health/2017/09/new-infographic-a-response-to-a-better-deal-on-drug-pricing

Filed under: Pricing

Alnylam’s rare disease drug shines in trial, paving way for a brand-new class of medicines

The positive results in the clinical trial help validate Alnylam’s $7 billion market valuation and pave the way for more drugs based on RNAi technology. https://www.statnews.com/2017/09/20/alnylam-drug-success/

Filed under: Company

Bristol, Roche tap Halozyme for tech platform

Between upfront, milestone and royalty payments, the separate licensing agreements could be worth more than $2 billion combined. http://www.biopharmadive.com/news/bristol-roche-tap-halozyme-for-tech-platform/504958/

Filed under: Company

Propeller Health Expands Digital Health R&D Partnership with GSK

NewsThe Propeller platform has been used by patients and physicians in over 55 commercial programs across the United States.Contributed Author: Propeller HealthTopics: Biotech https://www.dddmag.com/news/2017/08/propeller-health-expands-digital-health-r-d-partnership-gsk

Filed under: R&D

On Drug Pricing: FDA Backs Up Its Calls for Increased Competition

FDA Commissioner Scott Gottlieb has been very public in expressing his desire to provide increased competition and greater choice to American consumers in a bid to drive down prices of prescription medicines. Recently, the agency he oversees took some unusual steps to back up those statements with action. Last week, the FDA approved the use […] http://www.xconomy.com/san-diego/2017/08/21/on-drug-pricing-fda-backs-up-its-calls-for-increased-competition/

Filed under: Pricing

AstraZeneca ups investment in messenger RNA drugs with Ethris deal

FRANKFURT (Reuters) – AstraZeneca has stepped up its investment in messenger RNA drugs, a promising approach in genetic therapy, by spending more than 25 million euros ($29 million) on a research alliance with German biotech start-up Ethris.

https://www.reuters.com/article/us-astrazeneca-ethris-idUSKCN1B10ZR

Filed under: Company

Amgen And Humana Partner For Improved Health Outcomes And Efficiency

THOUSAND OAKS, Calif. and LOUISVILLE, Ky., Aug. 17, 2017 /PRNewswire/ — Two of the nation’s leading health organizations, health and well-being company Humana Inc. (NYSE: HUM) and biotechnology company Amgen (NASDAQ:AMGN), have teamed up to identify opportunities to improve health… http://www.prnewswire.com/news-releases/amgen-and-humana-partner-for-improved-health-outcomes-and-efficiency-300506215.html

Filed under: Company

Pfizer spinoff Zoetis ups 2017 guidance, eyes more M&A for future growth

What does Pfizer animal health spinoff Zoetis share with its former parent, aside from its lineage? They’re both under pressure from investors to drive growth through acquisitions. Zoetis met second-quarter expectations and brightened its forecast for the rest of the year, and now it’s looking to M&A to drive further growth. http://www.fiercepharma.com/financials/pfizer-spinoff-zoetis-ups-2017-guidance-eyes-m-a-for-future-growth

Filed under: Company

Takeda begins new R&D link-up with Molecular Templates

Takeda is increasing its R&D investment in oncology with a collaboration with Texas biotech Molecular Templates. The Japanese
The post Takeda begins new R&D link-up with Molecular Templates appeared first on Pharmaphorum. https://pharmaphorum.com/news/takeda-begins-new-rd-link-molecular-templates/

Filed under: R&D

GSK looks to exit rare diseases

The British drugmaker is putting its rare disease business up for sale amid a company-wide refocusing. http://www.biopharmadive.com/news/glaxosmithkline-gsk-rare-disease-sell-divest-strimvelis/448087/

Filed under: Company

Lilly puts two-thirds of mid-phase cancer pipeline up for sale in major shake up of R&D priorities

Eli Lilly is seeking partners for two-thirds of its mid-phase oncology compounds. The Big Pharma wants to offload six phase 2 candidates to focus its R&D dollars on a clutch of early to mid-stage assets it thinks can become the new standard of care. http://www.fiercebiotech.com/biotech/lilly-puts-two-thirds-mid-phase-cancer-pipeline-up-for-sale-major-shake-up-r-d-priorities

Filed under: Company

Eli Lilly licenses Adimab antibody discovery and optimization tech

Adimab, LLC is transferring its proprietary antibody discovery and optimization platform to Lilly research sites in San Diego and New York. http://www.outsourcing-pharma.com/Preclinical-Research/Eli-Lilly-licenses-Adimab-antibody-discovery-and-optimization-tech

Filed under: R&D

Sanofi to Acquire Protein Sciences

NewsAcquisition adds recombinant-based influenza vaccine to Sanofi Pasteur’s portfolio.Contributed Author: SanofiTopics: Pharma Mergers & Acquistions https://www.dddmag.com/news/2017/07/sanofi-acquire-protein-sciences

Filed under: Company

Perspectives: More Transparent Pricing System Would Help Untangle Confusion Around High Costs

Read recent commentaries about drug-cost issues. http://khn.org/morning-breakout/perspectives-more-transparent-pricing-system-would-help-untangle-confusion-around-high-costs/

Filed under: Pricing

Trovagene Announces Agreement with Novogene for NextCollect™ in China

SAN DIEGO, July 12, 2017 /PRNewswire/ — Trovagene, Inc. (NASDAQ: TROV), today announced that they have entered into an agreement with Novogene Co. Ltd., a leading global provider of genomic services and solutions with cutting edge next-generation sequencing (NGS) and the largest sequ… http://www.prnewswire.com/news-releases/trovagene-announces-agreement-with-novogene-for-nextcollect-in-china-300486641.html

Filed under: Emerging Markets

Alnylam Buckles Down On A Belt Of Rare Diseases

https://seekingalpha.com/article/4087017-alnylam-buckles-belt-rare-diseases

Filed under: Company

Regulation of orphan drugs within the EU

https://www.europeanpharmaceuticalreview.com/article/62846/3-17-gerstberger/

Filed under: General

Categories